a tumor necrosis factor antagonist to the subject.

8. The method of claim 6, wherein the tumor necrosis factor antagonist is an anti-tumor necrosis factor antibody or antigen-binding fragment thereof.

9. The method of claim 8, wherein the antibody is selected from the group consisting of a humanized antibody and a resurfaced antibody or antigen-binding fragment thereof.

10. The method of claim 8, wherein the antibody binds to an epitope included in amino acid residues of about 87-108 (SEQ ID NO:1) or about 59-80 (SEQ ID NO:2) of hTNFα.

12. The method of claim 8, wherein the antibody is a chimeric antibody, said chimeric antibody comprising (a) a non-human variable region specific for TNF or an antigen-binding portion thereof and (b) a human constant region.

13. The method of claim 12, wherein the chimeric antibody binds to an epitope included in amino acid residues of about 87-108 (SEQ ID NO:1) or about 59-80 (SEQ ID NO:2) of hTNFα.

14. The method of claim 12, wherein the chimeric antibody is monoclonal antibody cA2.

E1

15. (Thrice Amended) The method of claim 12, wherein the chimeric antibody competitively inhibits binding of TNFα to monoclonal antibody cA2.

29. A method of decreasing plasma fibrinogen in a subject diagnosed as suffering from or at risk of thrombosis comprising administering a therapeutically effective amount of a tumor necrosis factor antagonist to the subject.

30. The method of claim 29, wherein the tumor necrosis factor antagonist is an anti-tumor necrosis factor antibody or antigen-binding fragment thereof.

31. The method of claim 30, wherein the antibody is selected from the group consisting of a humanized antibody and a resurfaced antibody or antigen-binding fragment thereof.

32. The method of claim 30, wherein the antibody binds to an epitope included in amino acid residues of about 87-108 (SEQ ID NO:1) or about 59-80 (SEQ ID NO:2) of hTNFα.

34. The method of claim 30, wherein the antibody is a chimeric antibody, said chimeric antibody comprising (a) a non-human variable region specific for TNF or an antigen-binding portion thereof and (b) a human constant region.

35. The method of claim 34, wherein the chimeric antibody binds to an epitope included in amino acid residues of about 87-108 (SEQ ID NO:1) or about 59-80 (SEQ ID NO:2) of hTNFα.

36. The method of claim 34, wherein the chimeric antibody competitively inhibits binding of TNFα to monoclonal antibody cA2.